Select Publications

Bepler G et al. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 2008;15(2):130-9. Abstract

Hecht JR et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Gastrointestinal Cancers Symposium 2008a;Abstract 273.

Hecht JR et al. Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium 2008b;Abstract 279.

Punt CJ et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Proc ASCO 2008;LBA4011.

Saltz LB et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007;25(29):4557-61. Abstract

Uchida K et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal
adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008;8(1):386. Abstract

Vallböhmer D et al. Molecular determinants of irinotecan efficacy. Int J Cancer 2006;119(10): 2435-42. Abstract